Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression.Key topics included:The current treatment algorithms for late relapse refractory multiple myelomaThe significance of antigen expression in guiding treatment decisionsThe role of bispecific antibodies like teclistamab and talquetamabManaging side effects and improving patient quality of lifeThe importance of collaboration between community hematologists and tertiary care centersJoin us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease! Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media:⁠X/Twitter: https://x.com/oncbrothers⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/ Subscribe for more insights and updates on oncology treatments!#MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers